12 Jun 06
Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.
Datamonitor Expert Views
12 Jun 06
Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
10 Jun 06
Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
09 Jun 06
Today we report on the FDA approval of Merck's HPV vaccine, the first such vaccine to be approved in the US; and a candidate treatment for various cardiovascular diseases
08 Jun 06
DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from blood pressure control. In addition we report on European approval of Thelin, Encysive’s candidate for the treatment of pulmonary hypertension
08 Jun 06
Osteoarthritis is the leading cause of disability in the US, and is estimated to be the eighth most common cause of disability worldwide, with around 89 million adults in the seven major markets having a form of symptomatic osteoarthritis. OA therefore offers an attractive commercial target. However, relatively low disease awareness and Cox-2s controversy have curbed the market's potential so far.
07 Jun 06
DailyUpdates 7th June: ASCO is finished for this year now but not before Gloucester Pharmaceuticals managed to counter yesterday’s news from Merck with clinical data on their own HDAC inhibitor. Together this means that the two most advanced HDAC inhibitors are progressing nicely towards the market and soon, we hope, cancer patients will be offered another option. Also today we report on Pfizer’s very early stage serotonin 5-HT receptor ligands, a class that is emerging from the arena of IBS to
05 Jun 06
(The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX vaccine for the treatment of CML. In their phase 2 trial the company reports that a complete molecular response is seen in 25% of patients whose treatment included GVAX - this compares to historical data of about 10% in patients not receivin
02 Jun 06
Psychiatrists attending this year’s Annual Psychiatric Association meeting heard new findings from the controversial CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) programme. New data suggest an older typical antipsychotic drug is more cost effective and has the same cognitive benefits as newer atypical drugs. Previous results suggested the older first generation drug is equally effective and well-tolerated clinically, compared to newer atypicals but the study design was m
Olwen Glynn Owen - PharmiWeb Field Reporter
31 May 06
DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured today
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.